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Clinical Outcome of Small Cell Lung Cancer with
Pericardial Effusion but without Distant Metastasis
Seiji Niho, MD,* Kaoru Kubota, MD,* Kiyotaka Yoh, MD,* Koichi Goto, MD,*
Hironobu Ohmatsu, MD,* Keiji Nihei, MD,† Yuichiro Ohe, MD,* and Yutaka Nishiwaki, MD*
Background: Pericardial effusion is defined as M1a in the Union
Internationale Contre le Cancer seventh tumor, node, metastasis
edition for lung cancer. The clinical course of small cell lung cancer
(SCLC) with pericardial effusion but without distant metastasis
(M1a) has not been adequately investigated.
Methods: The medical records of patients with SCLC treated at the
National Cancer Center Hospital East between July 1992 and De-
cember 2007 were reviewed. During this period, 766 patients were
newly diagnosed as having SCLC. Thirty-three of the 416 patients
with limited disease (LD) SCLC (8%) had pericardial effusion.
Seventy-nine patients with LD-SCLC (19%) had ipsilateral pleural
effusion or dissemination. Of these, 16 patients had both pericardial
and ipsilateral pleural effusion. We divided the 96 M1a patients into
two subgroups: group A (n  33) included patients with pericardial
effusion, and group B (n  63) included patients with ipsilateral
pleural effusion or disseminated pleural nodules but without peri-
cardial effusion.
Results: The median survival time among the patients with LD-M1a
was 13.4 months (95% confidence interval: 10.7–16.6 months), and
the 1-, 2-, 3-, and 5-year survival rates were 56%, 18%, 9%, and 8%,
respectively. The survival of the patients with LD-M1a was inter-
mediate between those of the patients with LD-M0 and patients with
extensive disease M1b (p  0.0001). The overall survival period
was not statistically different between groups A and B (p 0.5182).
Nineteen patients in group A received chemoradiotherapy, but only
two patients survived for more than 2 years (2- and 5-year survival
rate: 11% both). Twenty-six patients in group B received chemora-
diotherapy, and four patients survived for more than 5 years (5-year
survival rate: 18%).
Conclusions: Long-term survival was achieved among patients with
SCLC with pericardial effusion but without distant metastasis who
successfully underwent chemoradiotherapy, although 5-year sur-
vival rate in these patients was relatively lower than in patients with
SCLC with ipsilateral pleural effusion but without pericardial effu-
sion or distant metastasis.
Key Words: Small cell lung cancer, Limited disease, Pericardial
effusion.
(J Thorac Oncol. 2011;6: 796–800)
Lung cancer is the leading cause of cancer-related deathsworldwide. Small cell lung cancer (SCLC) accounts for
approximately 15% of all forms of lung cancer. Compared
with non-SCLC, SCLC grows rapidly, quickly disseminates
to the regional lymph nodes and distant sites, and is sensitive
to chemotherapy with a response rate of 70 to 80%. The
Veterans Administration Lung Study Group proposed a clin-
ical two-stage system for SCLC that distinguishes limited
disease (LD) and extensive disease (ED). LD is defined as
being limited to one hemithorax, including mediastinal, con-
tralateral hilar, and ipsilateral supraclavicular lymph nodes,
whereas ED represents tumor spread beyond these regions.1
The current standard care for LD-SCLC is a combination of
chemotherapy and thoracic radiotherapy (TRT). Conversely,
ED-SCLC is treated with chemotherapy alone. The original
definition of LD was a tumor volume that could be encom-
passed by a reasonable radiotherapy plan. According to the
International Association for the Study of Lung Cancer
(IASLC)’s consensus report, however, the classification of
LD-SCLC includes bilateral hilar or supraclavicular nodal
involvement and ipsilateral pleural effusion, regardless of
whether the cytological findings are positive or negative.2
Pericardial effusion has not been defined precisely.
In 2007, the IASLC proposed a new tumor, node,
metastasis (TNM) classification for lung cancer,3–6 and the
Union Internationale Contre le Cancer (UICC) seventh TNM
edition has been available since 2009. According to the UICC
seventh TNM edition, malignant pleural or pericardial effu-
sion and tumor with pleural nodules are defined as M1a,
leading to stage IV. An analysis of 12,620 patients with
SCLC in the IASLC database demonstrated that patients who
have ipsilateral pleural effusion without extrathoracic metas-
tases (M1a) have a survival that is intermediate between
stages I and III without effusion and stage IV. Nevertheless,
no information regarding the presence of pericardial effusion
is available in the IASLC database.7
Our previous retrospective analysis also demonstrated
that the survival of patients with LD-SCLC with ipsilateral
pleural effusion was intermediate between those of patients
with LD without ipsilateral pleural effusion and patients with
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ED, and long-term survival was achieved by patients with
LD-SCLC who successfully underwent definitive TRT after
their ipsilateral pleural effusion had disappeared after induc-
tion chemotherapy.8 In this retrospective study, we investi-
gated the clinical course and overall survival among patients
with LD-SCLC with pericardial effusion, compared with
those among patients with ED-SCLC or LD-SCLC with or
without ipsilateral pleural effusion.
PATIENTS AND METHODS
In this study, LD-SCLC was defined as disease limited
to one hemithorax, including mediastinal, contralateral hilar,
and supraclavicular lymph nodes, ipsilateral pleural effusion,
and pericardial effusion; ED-SCLC was defined as tumor
spread beyond these manifestations.
We retrospectively reviewed the medical records of
patients with lung cancer treated at the National Cancer
Center Hospital East between July 1992 and December 2007.
During this period, 766 patients were newly diagnosed as
having SCLC. Four hundred sixteen patients were diagnosed
as having LD-SCLC and 350 were diagnosed as having
ED-SCLC using conventional staging procedures, including a
medical history and physical examination, chest radiography,
computed tomography (CT) scan of the chest, CT scan or
ultrasound of the abdomen, bone scan, and CT scan or
magnetic resonance imaging of the brain. Thirty-three of the
416 patients with LD-SCLC (8%, 95% confidence interval
[CI]: 6–11%) had pericardial effusion and were included in
this study. Seventy-nine of the 416 patients with LD-SCLC
(19%, 95% CI: 15–23%) had ipsilateral pleural effusion or
dissemination. Four patients had a disseminated mass without
pleural effusion detected using CT scan. Sixteen patients with
LD-SCLC had both pericardial and ipsilateral pleural effu-
sion. Therefore, 63 patients with LD-SCLC had ipsilateral
pleural effusion or dissemination without pericardial effu-
sion. We divided the 96 M1a patients into two subgroups:
group A included patients with pericardial effusion, and
group B included patients without pericardial effusion. Group
B patients had ipsilateral pleural effusion or disseminated
pleural nodules (Figure 1).
The overall survival time was defined as the interval
between the start of treatment and death or the final follow-up
visit. The median overall survival time was estimated using
the Kaplan-Meier analysis method.9 Survival data were com-
pared among the groups using a log-rank test. This study was
approved by an institutional review board.
RESULTS
The patient characteristics are listed in Table 1. Eighty-
three percent of the patients were male, and 81% had a
performance status of 0 or 1. Fifty-four percent of the patients
FIGURE 1. Patients with small cell lung cancer with M1a.
Group A included patients with pericardial effusion, and group
B included patients with ipsilateral pleural effusion or dissemi-
nated pleural nodules, but without pericardial effusion.
TABLE 1. Patient Characteristics
ED-SCLC
(M1b)
LD-SCLC with
Pericardial Effusion
(M1a) (Group A)
LD-SCLC with Ipsilateral
Pleural Effusion but without
Pericardial Effusion (M1a) (Group B)
LD-SCLC
(M0)
No. of patients 350 33 63 320
Sex
Male 291 29 50 262
Female 59 4 13 58
Age (yr)
Median 66 67 68 66
Range 28–85 37–82 46–83 22–87
Performance status
0 22 0 4 108
1 224 25 47 190
2 63 6 9 15
3–4 41 2 3 7
Treatment delivered
Chemotherapy 316 14 36 50
Chemoradiotherapy 25 19 26 224
Surgery  chemotherapy 0 0 0 33
Surgery alone 0 0 0 10
Best supportive care 9 0 1 3
LD, limited disease; SCLC, small cell lung cancer; ED, extensive disease.
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received chemotherapy, and 38% received chemoradiother-
apy. Six percent of the patients underwent surgical resection
with or without adjuvant chemotherapy. Among the 96 pa-
tients with LD-M1a, all but one patient received chemother-
apy (n  50) or chemoradiotherapy (n  45). Three patients
underwent TRT (twice daily, 45 Gy in total) concurrently
with the first course of chemotherapy. Four, 13, and four
patients underwent TRT (once daily, 50 Gy in total) concur-
rently with the second, third, and fourth courses of chemo-
therapy, respectively. Twenty-one patients underwent TRT
(once daily, 50 Gy in total) sequentially after chemotherapy.
Among the group A patients, 12 patients underwent TRT
concurrently with the third or fourth course of chemotherapy,
and seven patients underwent TRT sequentially after chemo-
therapy. TRT was conducted if the pericardial effusion dis-
appeared after induction chemotherapy. Among the group B
patients, 12 patients underwent TRT concurrently with che-
motherapy, and 14 patients underwent TRT sequentially
(Table 2). Thirteen patients received prophylactic cranial
irradiation of 25 Gy (seven patients in group A and six
patients in group B).
Figure 2 shows the survival of all 766 patients with
SCLC belonging to category M. The survival of patients
with LD-M1a was intermediate between those of patients
with LD-M0 and ED-M1b (p  0.0001). Six hundred
eighty-two patients have died. The median follow-up time
was 65.8 months, ranging from 3.2 to 160.1 months. The
median survival time among the patients with LD-M1a
was 13.4 months (95% CI: 10.7–16.6 months), and the 1-,
2-, 3-, and 5-year survival rates were 56%, 18%, 9%, and
8%, respectively.
Survival analyses for the subgroup of patients with
LD-M1a (n  96) are shown in Figures 3, 4 and Table 3.
Overall survival was not statistically different between
groups A and B (p  0.5182). All 14 patients who received
chemotherapy in group A died within 3 years. One patient in
group B who received chemotherapy as an initial treatment
survived for more than 5 years, but this patient received
chemoradiotherapy as a second-line treatment after a local
FIGURE 2. Overall survival among all 766 patients with M-
category small cell lung cancer. LD, limited disease; ED, ex-
tensive disease.
FIGURE 3. Overall survival among patients with M-cate-
gory small cell lung cancer, subgroups A and B. LD, limited
disease; ED, extensive disease.
FIGURE 4. Overall survival among M1a patients with small
cell lung cancer according to subgroups A, B, and initial
treatment delivered. CRT, chemoradiotherapy; CH, chemo-
therapy.
TABLE 2. Timing of Thoracic Radiotherapy in Patients with
M1a Small Cell Lung Cancer
Timing of Thoracic
Radiotherapy
LD-SCLC with
Pericardial
Effusion (M1a)
(Group A,
n  19)
LD-SCLC with Ipsilateral
Pleural Effusion but
without Pericardial
Effusion (M1a) (Group B,
n  26)
Concurrently with the
first course of
chemotherapy
0 3
Concurrently with the
second course of
chemotherapy
0 4
Concurrently with the
third course of
chemotherapy
8 5
Concurrently with the
fourth course of
chemotherapy
4 0
Sequentially after
chemotherapy
7 14
LD, limited disease; SCLC, small cell lung cancer.
Niho et al. Journal of Thoracic Oncology • Volume 6, Number 4, April 2011
Copyright © 2011 by the International Association for the Study of Lung Cancer798
recurrence. Four of the 26 patients who received chemora-
diotherapy in group B survived for more than 5 years (Ta-
ble 4). Conversely, only 2 of the 19 patients who received
chemoradiotherapy in group A survived for more than 2
years. One patient developed a local recurrence at 4 years and
10 months after the initiation of first-line chemoradiotherapy
and died of lung cancer 14 months later. The remaining
patient also developed a local recurrence at 2 years and 9
months after the initiation of first-line chemoradiotherapy and
received second-line chemotherapy. This patient was still
alive at the time of the data cutoff.
DISCUSSION
This retrospective analysis demonstrated that the sur-
vival of patients with SCLC and ipsilateral pleural or peri-
cardial effusion (M1a) was intermediate between those of M0
and M1b patients. It is suitable that patients with ipsilateral
pleural effusion or pericardial effusion belong to M1a cate-
gory in the UICC seventh TNM edition. No statistically
significant difference in the overall survival between M1a
patients with pericardial effusion (group A) and those with
ipsilateral pleural effusion but without pericardial effusion
(group B) was observed. Among the patients who success-
fully underwent chemoradiotherapy, the patients in group B
had 2-, 3-, and 5-year survival rates of 42%, 22%, and 18%,
respectively, whereas the patients in group A had a 2-year
survival rate of only 11%. Our previous retrospective analy-
ses demonstrated that the median survival time of patients
with cytologically positive and cytologically negative pleural
effusion were 9.3 and 12.7 months, respectively. Further-
more, all 11 patients with cytologically positive pleural effu-
sion died within 3 years.8 Long-term survival for more than 5
years was achieved only by patients with cytologically neg-
ative pleural effusion. We speculate that an inflammatory
process, such as atelectasis, causes ipsilateral pleural effusion
in some patients. Conversely, most pericardial effusion is
believed to be malignant. Therefore, long-term survival was
seldom achieved by patients with pericardial effusion, even if
they received chemoradiotherapy.
Recently, the applicability of the UICC seventh TNM
edition for SCLC was investigated using the California Can-
cer Registry database. This database included 108 and 1518
M1a patients with pericardial effusion and pleural dissemi-
nation, respectively. No significant difference in overall sur-
vival was observed among patients with pleural or pericardial
effusion (median survival time: 7 versus 7 months, 2-year
survival rate: 16.7% versus 9.7%, respectively).10 These data
were comparable with our results. Nevertheless, no informa-
tion regarding the treatment performed for the M1a patients
was included in the previous article.
Our retrospective analysis has several limitations. First,
the number of M1a patients with pericardial effusion was
only 33, because only 8% of the patients with LD-SCLC
exhibited pericardial effusion. Second, we did not conduct a
cytological examination of the pericardial effusion. Pericar-
dial puncture or drainage is usually performed in patients
with cardiac tamponade. None of the patients in group A had
cardiac tamponade; therefore, a pericardial puncture was
technically difficult. Third, examination period was more
than 15 years, from 1992 to 2007. Irinotecan, active for
SCLC, has been commonly used from 2000 in Japan. Patients
in this study were treated with a potential range of different
chemotherapeutic agents during the period, which was not
controlled.
Only 2 of 19 patients (11%) who received chemoradio-
therapy in group A survived for more than 3 years. Con-
TABLE 3. Survival Data
Subgroup
No. of
Patients
Median Survival
Time (mo) (95% CI)
1-yr Survival
Rate (%)
2-yr Survival
Rate (%)
3-yr Survival
Rate (%)
5-yr Survival
Rate (%)
ED (M1b) 350 9.2 (8.5–10.0) 34 7 3 2
LD (M0) 320 22.0 (20.0–23.5) 74 43 33 22
LD with pericardial effusion
(group A)
33 14.2 (9.1–17.5) 61 12 6 6
Receiving CRT 19 17.0 (13.6–21.0) 89 11 11 11
Receiving Chemotherapy 14 8.8 (4.7–11.1) 21 14 0 0
LD with ipsilateral pleural effusion
but without pericardial
effusion (group B)
63 12.7 (10.2–16.7) 54 21 11 9
Receiving CRT 26 21.4 (16.7–28.2) 85 42 22 18
Receiving chemotherapy 36 9.3 (6.3–11.8) 33 6 3 3
CI, confidence interval; ED, extensive disease; LD, limited disease; CRT, chemoradiotherapy.
TABLE 4. Six Patients with M1a Small Cell Lung Cancer
who Survived for More Than 5 yr
Age
(yr) Sex Group Initial Treatment
Survival
Time (mo) State
64 M A Chemoradiotherapy 72.6 Dead
70 F B Chemoradiotherapy 146.5 Alive
53 M B Chemotherapya 140.4 Alive
73 F B Chemoradiotherapy 138.0 Alive
72 M B Chemoradiotherapy 117.0 Alive
68 M B Chemoradiotherapy 65.5 Alive
a This patient received chemoradiotherapy as a second-line treatment after a local
recurrence. Therefore, all six patients received chemoradiotherapy and achieved long-
term survival for more than 5 yr.
M, male; F, female.
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versely, all 14 patients who did not receive chemoradiother-
apy in group A died within 3 years. TRT probably improves
local control and achieves long-term survival in some pa-
tients. Definitive TRT is recommended in M1a patients with
SCLC, if ipsilateral pleural or pericardial effusion has disap-
peared after induction chemotherapy.
In conclusion, the survival of patients with SCLC and
ipsilateral pleural or pericardial effusion (M1a) is intermedi-
ate between those of M0 and M1b patients. No statistically
significant difference in the overall survival of M1a patients
with pericardial effusion and those with ipsilateral pleural
effusion but without pericardial effusion was observed. Long-
term survival was achieved among M1a patients with peri-
cardial effusion who successfully underwent chemoradiother-
apy, although 5-year survival rate in these patients was
relatively lower than in M1a patients with ipsilateral pleural
effusion but without pericardial effusion.
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